文献速递细菌感染、耐药与抗菌药物

局部特拉万星与万古霉素在小鼠眼部模型中的体内耐受性比较

In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究在小鼠最大耐受剂量模型中比较了局部特拉万星与万古霉素(25和50 mg/mL)的眼部耐受性。结果显示万古霉素呈剂量依赖性毒性,而特拉万星25 mg/mL耐受性良好,仅1/4小鼠出现轻度结膜水肿和眯眼,无眼睑闭合。结论认为特拉万星25 mg/mL制剂在该模型中耐受性优于强化万古霉素制剂。

要点

  • 万古霉素25和50 mg/mL均引起全部小鼠充血、结膜水肿和眼睑闭合等剂量依赖性毒性。
  • 特拉万星25 mg/mL耐受性良好,仅1/4小鼠出现轻度结膜水肿和眯眼,无眼睑闭合。
  • 特拉万星50 mg/mL引起全部小鼠眼睑闭合、结膜水肿和充血,与万古霉素50 mg/mL毒性相似。

核心结论

  • 特拉万星25 mg/mL制剂在小鼠眼部模型中的耐受性优于受试的强化万古霉素制剂。
  • 这些发现支持对MDR革兰阳性眼部感染进行进一步的临床前评估。

研究设计与样本

  • 研究采用免疫健全雌性BALB/c小鼠的最大耐受剂量模型,共24只,分6组,每组4只。
  • 每组接受20次滴眼,间隔15分钟,持续5小时,药物为特拉万星或万古霉素(25或50 mg/mL)或匹配溶媒。
  • 溶媒包括特拉万星对应的250或500 mg/mL羟丙基-β-环糊精(HPβCD)和万古霉素对应的0.9% NaCl。
  • 末次给药后30分钟进行眼部刺激评分,并在1、3、5小时记录笼边观察。

主要发现

  • 万古霉素25 mg/mL组全部小鼠(4/4)出现充血、结膜水肿和眼睑闭合。
  • 万古霉素50 mg/mL组全部小鼠出现眼睑闭合、结膜水肿、充血和角膜干燥,其中2/4出现白色分泌物。
  • 特拉万星25 mg/mL组仅1/4小鼠出现轻度结膜水肿和眯眼,无眼睑闭合。
  • 特拉万星50 mg/mL组全部小鼠(4/4)出现眼睑闭合、结膜水肿和充血。
  • 250 mg/mL溶媒未引起临床相关眼部改变,但1/4小鼠出现眯眼;500 mg/mL溶媒引起全部小鼠(4/4)轻度结膜水肿和充血。

关键数值与推荐

  • 万古霉素25 mg/mL:4/4小鼠出现充血、结膜水肿和眼睑闭合。
  • 万古霉素50 mg/mL:4/4小鼠出现眼睑闭合、结膜水肿、充血和角膜干燥,2/4出现白色分泌物。
  • 特拉万星25 mg/mL:1/4小鼠出现轻度结膜水肿和眯眼,无眼睑闭合。
  • 特拉万星50 mg/mL:4/4小鼠出现眼睑闭合、结膜水肿和充血。
  • 溶媒:250 mg/mL HPβCD组1/4小鼠眯眼;500 mg/mL HPβCD组4/4小鼠轻度结膜水肿和充血;0.9% NaCl组未报告异常。

临床怎么用

  • 在临床前模型中,特拉万星25 mg/mL的眼部耐受性优于万古霉素25和50 mg/mL。
  • 该结果提示特拉万星25 mg/mL可能是眼部MDR革兰阳性感染局部治疗的候选制剂,但需进一步临床前和临床研究验证。

局限性

  • 研究为小鼠模型,样本量小(每组4只),结果外推到人类需谨慎。
  • 仅评估了短期(5小时内20次滴眼)耐受性,未评估长期用药安全性或疗效。
  • 未报告特拉万星25 mg/mL与万古霉素在感染模型中的疗效比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multicentre surveillance studies show increasing resistance among ocular MDR bacteria causing sight-threatening infections, especially MRSA. MRSA is associated with poor visual outcomes despite treatment with topical fortified vancomycin (25-50 mg/mL), the current standard of care. We previously demonstrated that telavancin exhibits approximately 16-fold greater in vitro potency than vancomycin against ocular MRSA isolates, with lower cytotoxicity. OBJECTIVES: To compare the in vivo ocular tolerability of topical telavancin and vancomycin at 25 and 50 mg/mL in a murine maximum-tolerated-dose model. METHODS: Immunocompetent female BALB/c mice (n = 24; six groups, four/group) received 20 instillations, 15 min apart over 5 h, of telavancin or vancomycin (25 or 50 mg/mL) or matching vehicles [250 or 500 mg/mL hydroxy-propyl-β-cyclodextrin (HPβCD) for telavancin; 0.9% NaCl for vancomycin]. Ocular irritation was graded 30 min after the final dose and cage-side observations were recorded 1, 3 and 5 h. RESULTS: Vancomycin showed dose-dependent toxicity. At 25 mg/mL, all mice (4/4) exhibited hyperaemia, chemosis and eyelid closure; at 50 mg/mL, all had eyelid closure, chemosis, hyperaemia and corneal dryness, and 2/4 had white discharge. Telavancin 25 mg/mL was well tolerated: only 1/4 displayed mild chemosis and squinting, with no eyelid closure. Telavancin 50 mg/mL caused eyelid closure, chemosis and hyperaemia in 4/4 mice. The 250 mg/mL vehicle caused no clinically relevant ocular changes, although 1/4 mice showed squinting; 500 mg/mL vehicle induced mild chemosis and hyperaemia in 4/4 mice. CONCLUSIONS: The telavancin 25 mg/mL formulation was better tolerated than the fortified vancomycin formulation tested in this model. These findings support further preclinical evaluation for MDR Gram-positive ocular infections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Fenniri I, Bispo PJM, Andre C, et al. In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model. J Antimicrob Chemother. 2026. PMID: 42483981. doi:10.1093/jac/dkag250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。